Market research
PHARM.AS Pharming Group N.V
AS EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 593M
- P/E ratio
- 83.8
- Analyst target
- 2.2368
- Dividend yield
- Not available
- Beta
- 0.07
Profile
Instrument facts
- Exchange
- AS
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL0010391025
- Market cap
- 593M
- P/E ratio
- 83.8
- Analyst target
- 2.2368
- Dividend yield
- Not available
- Beta
- 0.07
About
About Pharming Group N.V
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Research context
Pharming Group N.V appears in PyInvesting’s Amsterdam Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PHARM.AS discussion.
5 years, 6 months ago
Pharming Group N.V is currently in a long term downtrend where the price is trading 10.7% below its 200 day moving average.
From a valuation standpoint, the stock is 68.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Pharming Group N.V's total revenue rose by 1.0% to $46M since the same quarter in the previous year.
Its net income has dropped by 38.6% to $7M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.4% to $16M since the same quarter in the previous year.
Based on the above factors, Pharming Group N.V gets an overall score of 1/5.